{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Explores Durvalumab Plus Ceralasertib in Immunotherapy-Resistant Lung Cancer

Activity Steps

1 Activity
2 Take Test 3Certificate

Description

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Compare the objective response rate for the durvalumab plus ceralasertib treatment arm to the objective response rate for the other treatment combinations in the umbrella Phase II HUDSON study.
  2. Summarize results for the secondary objectives in this study (i.e., progression-free survival, disease control rate, and adverse events).

Disclosures

All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planner
Professions: Physician
Test Code: OT0524
Published: May 2024
Expires: 4/30/2026
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Categories: Hematology , Oncology
Specialties: Hematology, Oncology
Topics: Durvalumab plus Ceralasertib , Lung Cancer